There are a large number of LAG-3-targeted drugs undergoing clinical trials, such as relatlimab, eftilamidol alpha, LAG525, BI754111, TSR-033, and REGN3767, including treatments for melanoma, mesothelioma, breast cancer, lymphoma, myeloma, and leukemia, among other cancers [42, 43]. This evidence concerns the gene LAG3 and melanoma.